Novel Therapy for Male Hypogonadism

Robert Carrasquillo, Kevin Chu, Ranjith Ramasamy

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Purpose of Review: Hypogonadism and the treatment of low testosterone is increasingly a subject of medical inquiry and controversy. The few treatments that are FDA-approved such as testosterone topicals, injections, and pellets create significant demand from patients for treatments with more convenient means of administration, fewer adverse effects, and the ability to maintain male fertility. Off-label drugs are in abundant use for low testosterone, including selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors. Recent Findings: In this review, we summarize the evidence in support of commonly used treatments for male hypogonadism, as well as discuss recent updates in the development of novel therapeutics. Summary: New therapies include nasal testosterone, new oral testosterone formulations, anabolic-androgenic steroids, and selective androgen receptor modulators.

Original languageEnglish (US)
Article number63
JournalCurrent urology reports
Issue number8
StatePublished - Aug 1 2018


  • Clomiphene
  • Hypogonadism
  • SARM
  • Testosterone
  • Testosterone replacement therapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Novel Therapy for Male Hypogonadism'. Together they form a unique fingerprint.

Cite this